Your browser doesn't support javascript.
Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.
Chiuppesi, Flavia; Salazar, Marcela d'Alincourt; Contreras, Heidi; Nguyen, Vu H; Martinez, Joy; Park, Soojin; Nguyen, Jenny; Kha, Mindy; Iniguez, Angelina; Zhou, Qiao; Kaltcheva, Teodora; Levytskyy, Roman; Ebelt, Nancy D; Kang, Tae Hyuk; Wu, Xiwei; Rogers, Thomas; Manuel, Edwin R; Shostak, Yuriy; Diamond, Don J; Wussow, Felix.
  • Chiuppesi F; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Salazar MD; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Contreras H; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Nguyen VH; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Martinez J; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Park S; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Nguyen J; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Kha M; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Iniguez A; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Zhou Q; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Kaltcheva T; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Levytskyy R; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Ebelt ND; Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.
  • Kang TH; Department of Genomic core facility, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.
  • Wu X; Department of Genomic core facility, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.
  • Rogers T; University of California San Diego, School of Medicine, Division of Infectious Diseases and Global Public Health, 9500 Gilman Dr, La Jolla, CA 92093; Scripps Research, Department of Immunology and Microbiology, 10550 N Torrey Pines Rd, La Jolla, CA 92037.
  • Manuel ER; Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.
  • Shostak Y; Research Business Development, City of Hope, Duarte CA 91010, USA.
  • Diamond DJ; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
  • Wussow F; Department of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
bioRxiv ; 2020 Jul 02.
Article in English | MEDLINE | ID: covidwho-636653
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a novel vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Year: 2020 Document Type: Article Affiliation country: 2020.07.01.183236

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Year: 2020 Document Type: Article Affiliation country: 2020.07.01.183236